Amylyx Pharmaceuticals (AMLX) Other Operating Expenses (2022 - 2024)

Amylyx Pharmaceuticals has reported Other Operating Expenses for 3 years, with the latest figure at $37.0 million in Q3 2024.

• On a quarterly basis, Other Operating Expenses rose 609.31% year-over-year to $37.0 million in Q3 2024; TTM through Jun 2025 was $37.0 million, a 73.26% decrease from a year earlier, with the FY2024 full-year figure at $160.8 million, up 532.19% from the prior year.
• Other Operating Expenses was $37.0 million for Q3 2024 at Amylyx Pharmaceuticals, up from $7.4 million in the prior quarter.
• The five-year high for Other Operating Expenses was $116.4 million in Q1 2024, with the low at $172000.0 in Q3 2022.
• Average Other Operating Expenses over 3 years is $21.0 million, with a median of $5.6 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Other Operating Expenses jumped 2933.72% in 2023, then soared 32.94% in 2024.
• Over 3 years, Other Operating Expenses stood at $2.8 million in 2022, then jumped by 231.8% to $9.4 million in 2023, then jumped by 295.43% to $37.0 million in 2024.
• The last three Other Operating Expenses figures came in at $37.0 million (Q3 2024), $7.4 million (Q2 2024), and $116.4 million (Q1 2024), per Business Quant data.